4.7 Article

IL-17A as an Inducer for Th2 Immune Responses in Murine Atopic Dermatitis Models

Journal

JOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume 134, Issue 8, Pages 2122-2130

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1038/jid.2014.51

Keywords

-

Categories

Funding

  1. Ministries of Education, Culture, Sports, Science and Technology
  2. Janssen Pharmaceutical
  3. Japan Society for the Promotion of Science
  4. Grants-in-Aid for Scientific Research [13J02446] Funding Source: KAKEN

Ask authors/readers for more resources

Atopic dermatitis (AD) is generally regarded as a type 2 helper T (Th2)-mediated inflammatory skin disease. Although the number of IL-17A-producing cells is increased in the peripheral blood and in acute skin lesion of AD patients, the role of IL-17A in the pathogenesis of AD remains unclear. To clarify this issue, we used murine AD models in an IL-17A-deficient condition. In a repeated hapten application induced AD model, skin inflammation, IL-4 production in the draining lymph nodes (LNs), and hapten-specific IgG1 and IgE induction were suppressed in IL-17A-deficient mice. V gamma 4(+) gamma delta T cells in the skin-draining LNs and V gamma 5(-) dermal gamma delta T cells in the skin were the major sources of IL-17A. Consistently, in flaky-tail (Fig(ft/ft) ma/ma) mice, spontaneous development of AD-like dermatitis and IgE induction were attenuated by IL-17A deficiency. Moreover, Th2 differentiation from naive T cells was promoted in vitro by the addition of IL-17A. Taken together, our results suggest that IL-17A mediates Th2-type immune responses and that IL-17A signal may be a therapeutic target of AD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biotechnology & Applied Microbiology

Heat-Killed Levilactobacillus brevis as a Candidate Postbiotics Through Immunostimulation Mediated by Macrophage-Inducible C-Type Lectin

Tomoyuki Shimazu, Mai Suzuki, Ryo Takasaki, Asuka Besshi, Yuna Suzuki, Yoichiro Iwakura

Summary: This study investigated the relationship between lactic acid bacteria (LAB) and innate immune receptors. The researchers found that C-type lectin receptors (CLRs) are involved in the immune-stimulating function of LAB. The interaction between LAB and CLRs can reduce the levels of certain cytokines and is only observed in heat-killed LAB. These findings contribute to a better understanding of the immunomodulatory effects of LAB.

PROBIOTICS AND ANTIMICROBIAL PROTEINS (2023)

Article Infectious Diseases

The second nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan

Takamitsu Ohnishi, Shinichi Watanabe, Tetsuya Matsumoto, Hiroshi Yotsuyanagi, Junko Sato, Intestu Kobayashi, Shin Iinuma, Takashi Nagayama, Shuichiro Shibuya, Natsuki Ogawa, Ken Iozumi, Yasuyuki Nakajima, Yukiko Kurikawa, Motoko Kobayashi, Koma Matsuo, Hideyuki Ishikawa, Tadamichi Shimizu, Kiyohiro Tsutsui, Tatsuyoshi Kawamura, Ryuhei Okuyama, Mariko Seishima, Yoichi Akita, Chikatoshi Kasugai, Katsuaki Yano, Yasuhiko Tamada, Kimihiko Mizutani, Kenji Kabashima, Nanako Yamada, Masami Ikeda

Summary: The present study compared trends in antimicrobial resistance patterns in pathogens isolated from skin and soft-tissue infections (SSTIs) in Japan with those of a nationwide survey conducted in 2013. The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) did not differ significantly between the present study and the 2013 survey. However, the prevalence of methicillin-resistant coagulase-negative staphylococci (MRCNS) was higher in the present study compared to the 2013 survey. The susceptibility profiles of MRSA and MRCNS to various antibiotics were not significantly different between the two surveys. Continuous monitoring is important for guiding the appropriate treatment of SSTIs.

JOURNAL OF INFECTION AND CHEMOTHERAPY (2023)

Letter Dermatology

Non-invasive visualization of epidermal hypertrophy of pachydermoperiostosis

Takayoshi Komatsu-Fujii, Corrine Sison de Jesus, Takashi Nomura, Kenji Kabashima

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Dermatology

English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis

Hidehisa Saeki, Masashi Akiyama, Masatoshi Abe, Atsuyuki Igarashi, Shinichi Imafuku, Yukihiro Ohya, Norito Katoh, Hideto Kameda, Kenji Kabashima, Yuichiro Tsunemi, Michihiro Hide, Mamitaro Ohtsuki

Summary: This guidance provides information on the use of oral JAK inhibitors for the treatment of atopic dermatitis. It explains the role of oral JAK inhibitors in inhibiting the signal transduction of cytokines involved in the pathogenesis of atopic dermatitis. It also highlights the authorized oral JAK inhibitors for atopic dermatitis in Japan and emphasizes the importance of considering disease factors, treatment factors, and patient backgrounds in the selection of treatment options.

JOURNAL OF DERMATOLOGY (2023)

Review Dermatology

Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events

R. Bissonnette, L. F. Eichenfield, E. Simpson, D. Thaci, K. Kabashima, J. P. Thyssen, E. Guttman-Yassky, F. P. Nunes, M. Gamalo, F. Ahmad, M. Kuligowski, K. Sun, C. Pipper, A. W. Christensen, P. D'Angelo, M. Milutinovic, A. Guettner, J. I. Silverberg

Summary: Despite the lack of guidelines for analyzing clinical trial data in atopic dermatitis (AD), using the estimand framework can help standardize the analysis and incorporate intercurrent events. Intercurrent events, such as rescue therapy and sleep deprivation, frequently occur in AD trials and their inconsistent handling limits result interpretation. Applying the estimand framework, as guided by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), can improve AD trial design and analysis by providing more reflective and informative results for clinicians to make treatment selection.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Medicine, General & Internal

An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study

Emma Guttman-Yassky, Eric L. Simpson, Kristian Reich, Kenji Kabashima, Ken Igawa, Tetsuya Suzuki, Hirotaka Mano, Takeshi Matsui, Ehsanollah Esfandiari, Masutaka Furue

Summary: This study evaluated the efficacy and safety of the anti-OX40 antibody rocatinlimab in patients with moderate-to-severe atopic dermatitis. The results showed significant reductions in EASI score at week 16 in patients receiving rocatinlimab compared to placebo. The treatment led to progressive improvements in atopic dermatitis, which were maintained in most patients after treatment discontinuation, and it was well tolerated.

LANCET (2023)

Article Toxicology

Interleukin-6 regulates the expression of hepatic canalicular efflux drug transporters after cecal ligation and puncture-induced sepsis: A comparison with lipopolysaccharide treatment

Takashi Ashino, Yuki Nakamura, Hirokazu Ohtaki, Yoichiro Iwakura, Satoshi Numazawa

Summary: In the study of polymicrobial sepsis, pro-inflammatory cytokines play a vital role in regulating hepatic drug transporter expression. The research found that both CLP and LPS can reduce the expression of drug transporters, but IL-6 is the major factor in the downregulation of hepatic multidrug transporters caused by polymicrobial sepsis.

TOXICOLOGY LETTERS (2023)

Article Dermatology

Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis A Post Hoc Analysis of 6 Randomized Clinical Trials

Amy S. Paller, Jonathan I. Silverberg, Michael J. Cork, Emma Guttman-Yassky, Benjamin Lockshin, Alan D. Irvine, Moon Bum Kim, Kenji Kabashima, Zhen Chen, Yufang Lu, Ashish Bansal, Ana B. Rossi, Arsalan Shabbir

Summary: This study assessed the efficacy and safety of dupilumab in patients with severe erythrodermic atopic dermatitis (AD). The results showed that dupilumab significantly improved AD signs and symptoms, including affected body surface area, Eczema Area and Severity Index (EASI) score, and Pruritus Numerical Rating Scale (PP-NRS) score. The treatment also led to reductions in serum biomarker levels.

JAMA DERMATOLOGY (2023)

Correction Oncology

Correction to: IL-17A promotes fatty acid uptake through the IL-17A/IL-17RA/ p-STAT3/FABP4 axis to fuel ovarian cancer growth in an adipocyte-rich microenvironment (vol 69, pg 115, 2020)

Chunyan Yu, Xiulong Niu, Yongrui Du, Yan Chen, Xiaomei Liu, Lingling Xu, Yoichiro Iwakura, Xiaoxia Ma, Yan Li, Zhi Yao, Weimin Deng

CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)

Article Immunology

Downregulation of the gene expression of Cyp2c29 and Cyp3a11 by cecal ligation and puncture-induced sepsis is associated with interleukin-6

Takashi Ashino, Yuki Nakamura, Hirokazu Ohtaki, Yoichiro Iwakura, Satoshi Numazawa

Summary: Sepsis affects drug metabolism and the expression of cytochrome P450s. The study shows that cecal ligation and puncture (CLP) induces the expression of proinflammatory cytokines and leads to decreased survival in IL-6(-/-) mice. CLP also downregulates the expression of Cyp2c and Cyp3a11 genes, but this effect is abolished by IL-6 depletion.

INTERNATIONAL IMMUNOPHARMACOLOGY (2023)

Article Biochemistry & Molecular Biology

Arteriosclerosis Derived from Cutaneous Inflammation Is Ameliorated by the Deletion of IL-17A and IL-17F

Takehisa Nakanishi, Shohei Iida, Junko Maruyama, Hayato Urushima, Masako Ichishi, Yoshiaki Matsushima, Kento Mizutani, Yuichi Nakayama, Kyoko Sugioka, Mai Nishimura, Ai Umaoka, Yoichiro Iwakura, Makoto Kondo, Koji Habe, Daisuke Tsuruta, Osamu Yamamoto, Yasutomo Imai, Keiichi Yamanaka

Summary: The skin is a major immune organ that produces inflammatory cytokines in response to stimuli, leading to systemic inflammation. Inflammatory skin diseases like psoriasis and atopic dermatitis can cause vascular disorders like arteriosclerosis. However, the mechanism of arteriosclerosis in dermatitis and the role of cytokines are not fully understood. This study investigates the pathophysiology of arteriosclerosis and treatment options for inflammatory skin conditions.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Dermatology

Nemolizumab Improves Patient-Reported Symptoms of Atopic Dermatitis with Pruritus: Post Hoc Analysis of a Japanese Phase III Randomized Controlled Trial

Kenji Kabashima, Takayo Matsumura, Hiroshi Komazaki, Makoto Kawashima

Summary: This study investigated the impact of nemolizumab on the quality of life in patients with atopic dermatitis. The results showed that nemolizumab treatment improved sleep quality, interpersonal relationships, and work activities.

DERMATOLOGY AND THERAPY (2023)

Article Biochemistry & Molecular Biology

Mead acid inhibits retinol-induced irritant contact dermatitis via peroxisome proliferator-activated receptor alpha

Azusa Saika, Prabha Tiwari, Takahiro Nagatake, Eri Node, Koji Hosomi, Tetsuya Honda, Kenji Kabashima, Jun Kunisawa

Summary: Mead acid can suppress retinol-induced irritant contact dermatitis and prevent keratinocyte hyperproliferation and the expression of neutrophil chemoattractants through the PPAR-alpha pathway.

FRONTIERS IN MOLECULAR BIOSCIENCES (2023)

Review Immunology

Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies

Toshiaki Kogame, Gyohei Egawa, Kenji Kabashima

Summary: Recent studies have shown that Janus kinase (JAK) plays a crucial role in signal transduction for inflammatory diseases like atopic dermatitis (AD). Clinical trials using JAK inhibitors and biologic reagents have been successful in treating AD, indicating the efficacy of molecular-based therapies. However, there are concerns about the safety of JAK inhibitors, including severe heart disease. This article provides an overview of the molecular mechanisms of AD and discusses JAK-related biology as a target for AD treatment.

IMMUNOLOGICAL MEDICINE (2023)

Article Dermatology

Neutrophilic epitheliotropism, proposed as an auto-inflammatory condition of neutrophilic urticarial dermatosis including Schnitzler syndrome, is also observed in Japanese cases

Hitomi Nakaizumi, Naotomo Kambe, Hiroyuki Irie, Yo Kaku, Masakazu Fujimoto, Hajime Yoshifuji, Yasuhiro Kazuma, Kazumoto Katagiri, Takuro Kanekura, Kenji Kabashima

Summary: Schnitzler syndrome (SchS) is a rare autoinflammatory disease characterized by bone pain, recurrent fever, and other symptoms. A key feature of the syndrome is the presence of a persistent urticarial-like rash. Histopathological data suggests that neutrophilic epitheliotropism, or the tendency of neutrophils to infiltrate and affect epithelial tissue, can be a useful marker for diagnosing SchS and differentiating it from conventional urticaria. Understanding this characteristic is crucial for early diagnosis and appropriate treatment.

JOURNAL OF DERMATOLOGY (2023)

No Data Available